Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE) Revenue
Annual & quarterly revenue history · segment & region breakdown
XENE · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsXenon Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | -$0.01B | -100.00% |
| 2022-12-31 | $0.01B | -$0.01B | -48.83% |
| 2021-12-31 | $0.02B | -$0.01B | -42.68% |
| 2020-12-31 | $0.03B | +$0.03B | +371.02% |
| 2019-12-31 | $0.01B | +$0.01B | — |
| 2018-12-31 | $0.00B | -$0.00B | -100.00% |
| 2017-12-31 | $0.00B | -$0.00B | -82.75% |
| 2016-12-31 | $0.00B | -$0.01B | -88.43% |
Compare revenue vs peers
BiotechnologyCompare XENE revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Xenon Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Xenon Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Xenon Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
XENE revenue · 4 questionsXENE's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Xenon Pharmaceuticals Inc. SEC filings · GAAP · Xenon Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026